Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PA21 versus sevelamer carbonate in dialysis patients with hyperphosphataemia
2010-022011-19Phase 3Completed
- Sponsor
- CSL Vifor
- Start
- Oct 2010
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Sucroferric oxyhydroxide and sevelamer carbonate in hyperphosphatemia and chronic kidney disease (CKD) (4 arms), sponsored by CSL Vifor. Primary endpoint: Change in serum phosphate during 3-week randomized withdrawal period. Started Oct 2010; status: completed.
02
Drugs
Sucroferric oxyhydroxidesevelamer carbonate
03
Conditions
hyperphosphatemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2010-022011-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022011-19.